Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,083 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,116
- Phase 1823
- Phase 1/Phase 2481
- Phase 3349
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,083 total
- NCT05914662RecruitingPhase 2
Zanubrutinib plus BR for newly diagnosed symptomatic WM
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05915208Recruiting
Follow-up study for people with histiocytic disorders
This study is checking in over time with people who have a histiocytic disorder. It may help doctors better understand how these conditions behave and what follow-up care works best.
Birmingham, AlabamaAges birth–89 years - NCT05916469Recruiting
Hormone treatment for heavy periods in teens and young adults
This trial studies how a progestin hormone—given as an IUD or tablets—can help reduce heavy menstrual bleeding in people with certain bleeding-related conditions. It may help you by testing whether the treatment works and is practical for your situation.
Palo Alto, CaliforniaAges 10–24 - NCT05916638Recruiting
Testing a breathing pattern in people with sarcoidosis and TB
This trial looks at a specific “MoMa signature” related to breathing or lung signals in adults who have been diagnosed with both sarcoidosis and tuberculosis. It may help researchers understand how these conditions affect the body and improve how patients are monitored.
ParisAges 18 years+ - NCT05917405RecruitingPhase 2
Clofarabine vs fludarabine for AML before stem cell transplant
This Phase 2 study compares two chemotherapy medicines—clofarabine and fludarabine—given at a reduced intensity before an allogeneic stem cell transplant. It aims to see which regimen works better and is safer for people with AML who are eligible for this transplant approach.
Nantes, Loire AtlantiqueAges 18–99 - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT05921253RecruitingEarly Phase 1
Check a brain-heart device to reduce chemo heart risk
This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.
Oklahoma City, OklahomaAges 18–99 - NCT05921812Recruiting
Blood tests for lymphoma using small RNA markers
This study looks at tiny blood molecules called microRNAs to see if they can help diagnose non-Hodgkin's lymphoma. If you are newly diagnosed and have no other cancers, your blood test results may be compared to known patterns to improve diagnosis.
SohagAges 18–75 - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05924074Recruiting
Study of ferroptosis therapy in blood disorders with SF3B1 mutation
This study looks at ferroptosis (a type of cell stress that can affect blood-forming cells) in people with certain blood disorders linked to an SF3B1 gene change. It may help researchers understand whether targeting this pathway could improve outcomes.
PessacAges 18 years+ - NCT05924100RecruitingPhase 2
Luspatercept for lower red blood counts in MDS with del5q
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
AlessandriaAges 18 years+ - NCT05924347Recruiting
Imaging study to spot early spine changes in at-risk children
This study uses MRI and physical measurements to look for early signs of scoliosis (a side-bending of the spine) in children who are at higher risk. It may help doctors understand when scoliosis starts and improve early monitoring.
UtrechtAges 8–11 - NCT05924750RecruitingPhase 1
Testing a CD33-targeted drug for difficult AML
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
Hefei, AnhuiAges 18–75 - NCT05926063RecruitingPhase 4
Stopping antibiotics after 3 days for high-risk neutropenia
This study tests whether it is safe to stop broad antibiotics after 3 days in people at high risk of infection from low white blood cells (neutropenia) who are hospitalized with fever. It may reduce antibiotic exposure, while still watching closely to keep you safe.
Leuven, Vlaams-BrabantAges 16 years+ - NCT05927571RecruitingPhase 1
Cevostamab and elranatamab combination study for relapsed myeloma
This Phase 1 trial tests whether combining two targeted antibody medicines—cevostamab and elranatamab—is safe and whether it shows signs of activity in people whose multiple myeloma has come back or not responded. It’s early-stage, so the main goal is safety, dosing, and how the medicines behave in the body.
Camperdown, New South WalesAges 18 years+ - NCT05929222RecruitingPhase 3
Radiation with or without an antibody for early follicular lymphoma
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
Sassuolo, Modena (MO)Ages 18 years+ - NCT05929612RecruitingPhase 2
Low-dose targeted radiation alone for marginal zone lymphoma
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
Houston, TexasAges 18 years+ - NCT05929729RecruitingPhase 4
Brain study in women with iron deficiency anemia
This is a study that looks at how iron deficiency anemia may affect the brain, and it also checks whether giving iron through an IV is safe and helpful for some participants. You may be in an observation-only group or an iron-treatment group, depending on study testing.
Duarte, CaliforniaAges 16–60 - NCT05929976Recruiting
Study of gut and blood chemistry in children with new leukemia
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
New York, New YorkAges 3–18 - NCT05931718Recruiting
Track diagnosis and treatment in autoimmune blood count disorders
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
MilanAges 18 years+ - NCT05932680RecruitingPhase 2
Continue teclistamab for a limited time in responding patients
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
Little Rock, ArkansasAges 18 years+ - NCT05934513RecruitingPhase 1/Phase 2
Study drug GFH009 for relapsed lymphoma after prior treatments
This early-phase study tests GFH009 (given alone) in adults with peripheral T-cell lymphoma that has come back or not responded. It may help shrink lymphoma in people who have already tried several other treatments.
Guanzhou, GuangdongAges 18–75 - NCT05934084Recruiting
Lifestyle plan for heart and health after lymphoma remission
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
Ancona, AnconaAges 18–50 - NCT05935215RecruitingPhase 3
Switch from anti-C5 shots to iptacopan for aHUS
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
Nanjing, JiangsuAges 18–100
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,083 recruiting hematology studies from the U.S. registry right now, out of 7,730 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.